Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Stealth BioTherapeutics Corp

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.

Stealth BioTherapeutics

Careers at Stealth BioTherapeutics

Our Mission
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address.

We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.

Please be aware of the potential for scams claiming to represent Stealth BioTherapeutics in recruitment activities. Stealth exclusively uses @stealthbt.com e-mail addresses for recruitment purposes and does not conduct interviews via social media or other third-party sites. Please report any suspicious recruiting activity to us at careers@stealthbt.com and to the Internet Crime Complaint Center.

Sagamore Investments

Ocean Equity Partners

Pivotal bioVenture Partners

Atlantis Investment Management

BVCF

CMBC Capital Holdings

Kingdon Capital

Horizon Technology Finance

Morningside Venture Investments

Last month, we had the privilege of discussing varied pathways for patient-inspired drug development at #BIO2024. Our CEO, Reenie McCarthy, shared about our long-standing and ongoing focus on patient-directed drug development and spoke alongside I. Sika D. of Travere Therapeutics, Danae'​ Bartke of HCU Network America, Jessica Tome Garcia, Ph.D. of The Michael J. Fox Foundation for Parkinson's Research, and Stacey Frisk of The Rare Disease Company Coalition. 
 
In the eight years since the passage of the 21st Century Cures Act, patient involvement in drug development has exploded. Millions of families affected by serious conditions, particularly in #RareDisease, now have time-tested paths to follow in their pursuit of a life-changing treatment. But patient-focused drug development meetings (PFDDs) are only part of the story. In fact, different paths in drug development have emerged as varied as the challenges that patients themselves face every day. This session explored different roads taken by stakeholders to drive patient input into drug development, inspiring hope for those interested in progress toward novel therapies. #not2rare2care

We had a wonderful time connecting with others in the #MitochondrialDisease community at the United Mitochondrial Disease Foundation #MitoMed conference last week! Our CEO, Reenie McCarthy, presented an update on our clinical programs, emphasizing key learnings, the importance of perseverance, and the value of first approvals that can inform further research and advancements. We’re already looking forward to next year’s conference!

Thank you to the United Mitochondrial Disease Foundation for hosting a wonderful #MitoMed 2024 conference in Cleveland, OH! Thank you to everyone who stopped by our booth to learn more about our work in #mitochondrialdisease. It was a pleasure connecting with patients, families, advocates, researchers, clinicians, and members of the community. Until next year!

Join us at tomorrow’s virtual #MitochondrialDisease Caucus Congressional briefing, “Transforming Patient Outcomes in Mitochondrial Disease: Raising Awareness, Enabling Innovation, Driving Change.” Our CEO Reenie McCarthy will join Emily Milligan of the Barth Syndrome Foundation, Kira Mann of MitoAction, Dr. Hilary Vernon of the The Johns Hopkins University School of Medicine, and Andrew Dearth of the United Mitochondrial Disease Foundation to discuss the need for continued innovation in #MitochondrialMedicine across the patient journey – from diagnosis to drug development – and opportunities to chart a path forward. 
Register here: https://lnkd.in/ewkCbRZ3

#ICYMI: You can tune into the live replay of the recent EveryLife Foundation for Rare Diseases scientific workshop focused on the challenges and opportunities in developing much-needed therapies for ultra-rare diseases. Our CEO, Reenie McCarthy starts speaking at 1:48:40. #not2rare2care https://lnkd.in/dxJF89b

#MitoMed2024 is right around the corner and the Stealth team is excited to be in Cleveland sharing more about our work from our program in primary mitochondrial myopathy and our expanded access program. You can find all the conference details at https://umdfconference.org

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
net income	-61.05M -	-82.91M 35.81%	-96.71M 16.65%	-71.73M 25.83%	-57.46M 19.90%	-52.53M 8.58%
depreciation and amortization	312.54K -	346.87K 10.99%	309.04K 10.91%	284K 8.10%	232K 18.31%	77K 66.81%
deferred income tax
stock based compensation	1.83M -	1.29M 29.79%	1.28M 0.80%	3.24M 154.11%	4.22M 30.21%	4.18M 1.07%
change in working capital	4.88M -	8.13M 66.38%	3.43M 57.80%	-4.74M 238.21%	-8.29M 74.91%	-2.10M 74.71%
accounts receivables
inventory
accounts payables	767.84K -	4.55M 491.96%	3.57M 21.50%	-1.50M 142.12%	-6.14M 308.52%	-59K 99.04%
other working capital	4.12M -	3.58M 13.01%	-139.22K 103.89%	-3.24M 2,224.31%	-2.15M 33.59%	-2.04M 5.21%
other non cash items		3.31M -	19.62M 491.93%	24.95M 27.19%	7.75M 68.94%	5.40M 30.38%
net cash provided by operating activities	-54.02M -	-69.84M 29.28%	-72.08M 3.21%	-47.98M 33.43%	-53.54M 11.58%	-44.97M 16.00%
investments in property plant and equipment	-287.88K -	-160.95K 44.09%	-11.65K 92.76%	-130K 1,015.69%	-35K 73.08%	-67K 91.43%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites	105.36K -	-12.04K 111.42%			-25K -	250K 1,100%
net cash used for investing activites	-182.52K -	-172.99K 5.22%	-11.65K 93.26%	-130K 1,015.69%	-60K 53.85%	183K 405%
debt repayment			-686.55K -	-2.81M 308.57%	-7.48M 166.74%	-9.11M 21.77%
common stock issued				88.02M -	23.44M 73.37%	8.97M 61.71%
common stock repurchased
dividends paid
other financing activites	50.29M -	64.42M 28.09%	79.51M 23.43%	2.81M 96.46%	19.66M 598.76%	59.27M 201.44%
net cash used provided by financing activities	50.29M -	64.42M 28.09%	78.83M 22.37%	88.03M 11.67%	35.62M 59.54%	59.14M 66.03%
effect of forex changes on cash
net change in cash	-3.91M -	-5.59M 42.96%	6.74M 220.49%	39.91M 492.50%	-17.98M 145.05%	14.35M 179.80%
cash at beginning of period	13.62M -	9.71M 28.71%	4.12M 57.58%	10.86M 163.55%	50.77M 367.69%	32.79M 35.42%
cash at end of period	9.71M -	4.12M 57.58%	10.86M 163.55%	50.77M 367.69%	32.79M 35.42%	47.13M 43.76%
operating cash flow	-54.02M -	-69.84M 29.28%	-72.08M 3.21%	-47.98M 33.43%	-53.54M 11.58%	-44.97M 16.00%
capital expenditure	-287.88K -	-160.95K 44.09%	-11.65K 92.76%	-130K 1,015.69%	-35K 73.08%	-67K 91.43%
free cash flow	-54.31M -	-70.00M 28.89%	-72.09M 2.99%	-48.11M 33.26%	-53.57M 11.35%	-45.04M 15.93%

COM:STEALTHBT

Stealth BioTherapeutics

Last Close

0.32

15/11 21:00

Volume Today

1.30M

Avg: -

Preview